Moderna disputes NIH claims on Covid-19 vaccine patents, says it offered to make government co-owners
Moderna on Thursday afternoon issued a quick rebuttal to recent NIH claims on its Covid-19 vaccine patents, saying that the mRNA sequence for the vaccine was “selected exclusively by Moderna scientists using Moderna’s technology” and without input of three NIH scientists. The company also said that it attempted to name NIH as co-owners on the patent in September.
“For those who would seek to twist Moderna’s good faith application of U.S. patent law into something else, nothing could be further from the truth. Moderna remains the only company to have pledged not to enforce its COVID-19 intellectual property during the pandemic,” the company said in a statement. NIH did not immediately respond to a request for comment.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.